Philip J. Facchina, Chief Strategy Officer and Principal of SurgCenter Development, Joins Mesoblast Board
29. März 2021 08:00 ET
|
Mesoblast Limited
NEW YORK, March 29, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that Philip J....
Mesoblast Closes US$110/A$138 Million Financing Led by US Strategic Investor Group
08. März 2021 20:03 ET
|
Mesoblast Limited
NEW YORK, March 08, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today the successful...
Mesoblast Completes US$110/A$138 Million Financing Led by US Strategic Investor Group
02. März 2021 07:00 ET
|
Mesoblast Limited
NEW YORK, March 02, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) announced today it has entered into subscription agreements for a total of US$110 million via the issue of 60...
Positive Outcomes of First Children Treated With Remestemcel-L for Multisystem Inflammatory Syndrome (MIS-C) and Heart Failure Post-COVID-19 Published in Pediatrics
17. Februar 2021 06:00 ET
|
Mesoblast Limited
NEW YORK, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that Pediatrics...
Mesoblast Phase 3 Trial Shows That a Single Injection of Rexlemestrocel-L + Hyaluronic Acid Carrier Results in at Least Two Years of Pain Reduction With Opioid Sparing Activity in Patients With Chronic Low Back Pain Due to Degenerative Disc Disease
10. Februar 2021 18:42 ET
|
Mesoblast Limited
NEW YORK, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced results from the Phase...
Mesoblast Corporate Update
10. Februar 2021 17:35 ET
|
Mesoblast Limited
NEW YORK, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to provide a...
Mesoblast Operational and Financial Highlights for Quarter Ended December 31, 2020
28. Januar 2021 19:05 ET
|
Mesoblast Limited
NEW YORK, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on its...
Mesoblast Presents Heart Failure Phase 3 Trial Results at Investor Healthcare Conference
11. Januar 2021 17:10 ET
|
Mesoblast Limited
NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that its Chief Executive...
Single Dose of Rexlemestrocel-L Provides Substantial and Durable Reduction in Heart Attacks, Strokes and Cardiac Death in Patients With Chronic Heart Failure
10. Januar 2021 23:26 ET
|
Mesoblast Limited
NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced additional results...
Mesoblast Webcast – Update on COVID-19 ARDS Trial
17. Dezember 2020 22:07 ET
|
Mesoblast Limited
NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to provide...